Krebs Biochemicals & Industries Ltd
Pharmaceuticals & Biotechnology | Small Cap
Krebs Biochemicals & Industries Ltd, operating in the Healthcare Services sector, shows a mixed financial performance. The company exhibits strengths in solvency, efficiency, and growth, but struggles with liquidity, coverage, financial metrics, and profitability. While the company showcases good performance in managing its debts and generating profits from its operations, it faces challenges in meeting its short-term obligations and ensuring consistent revenue growth. The negative profitability margins and low coverage ratios raise concerns about the company's financial sustainability. Overall, the company needs to address its liquidity and profitability issues to improve its financial health and stability.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsHighly Undervalued
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio7.20
- Financial Ratio2.40
- Profitability Ratio2.00
- Efficiency Ratio6.00
- Coverage Ratio2.00
- Solvency Ratio4.40
- Liquidity Ratio2.00
- Peer Assessment
- Management AssessmentWeak
- Risk AssessmentWeak
- 1 HourBullish
- 2 HoursBullish
- 4 HoursBullish
- 1 DayNeutral
- 1 WeekNeutral
- 1 MonthBullish
Krebs Biochemicals & Industries Ltd, operating in the Healthcare Services sector, shows a mixed financial performance. The company exhibits strengths in solvency, efficiency, and growth, but struggles with liquidity, coverage, financial metrics, and profitability. While the company showcases good performance in managing its debts and generating profits from its operations, it faces challenges in meeting its short-term obligations and ensuring consistent revenue growth. The negative profitability margins and low coverage ratios raise concerns about the company's financial sustainability. Overall, the company needs to address its liquidity and profitability issues to improve its financial health and stability.
Overall Valuation Score
P/E RATIO (TTM)
-5.17
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
-5.27
P/B RATIO
-0.90
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
3.31
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
-4.29
EV/EBITDA RATIO
-21.80
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹65.89 as on Jun 19, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company exhibits strong growth in operating profit, EPS, and net income, but revenue and assets have declined. This suggests improved profitability despite revenue challenges. The company's ability to grow profits faster than revenue indicates enhanced operational efficiency. However, declining revenue and assets raise concerns about sustainability. Focus on revenue generation and asset growth is essential for long-term success.
| Growth Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 63.64 | 11.11 | -13.33 | -3.85 | -14 |
| Operating Profit Growth Rate | -5.26 | 88.89 | -52.94 | -43.75 | 66.67 |
| Earnings Per Share (EPS) Growth | -9.91 | 42.91 | -44.55 | -20.09 | 36.61 |
| Asset Growth Rate | 19.5 | -7.89 | 1.71 | -5.06 | |
| Net Income Growth Rate | -3.45 | 60.71 | -44.44 | -20 | 35 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios reflect a concerning financial position. Negative adjusted EPS, cash EPS, and book value per share indicate poor profitability and asset value. The lack of dividend payments and moderate capital expenditures further highlight financial challenges. Addressing these issues is crucial for restoring financial stability and investor confidence.
| Financial Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | -14 | -20.45 | -11.36 | -9.09 | -12.33 |
| Cash Earnings Per Share (Cash EPS) | -11.5 | -17.73 | -8.18 | -5.91 | -9.09 |
| Book Value Per Share | -21 | -34.09 | -45 | -54.09 | -66.36 |
| Dividend Per Share (DPS) | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 17.8 | 27.1 | 15.2 | 7.3 | 3.4 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability ratios are significantly negative, indicating poor financial performance. Negative gross profit margin, ROCE, ROE, ROA, operating margin, and net margin raise severe concerns about its ability to generate profits. Addressing these issues is essential for ensuring its long-term sustainability.
| Profitability Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Gross Profit Margin | -42.59 | -66.67 | -44.23 | -32 | -51.16 |
| Return on Capital Employed (ROCE) | -40 | -57 | -29 | -19 | -30 |
| Return on Equity (ROE) | |||||
| Return on Assets (ROA) | -11.32 | -17.89 | -9.14 | -5.06 | -8.88 |
| Operating Margin | -33.33 | -56.67 | -30.77 | -18 | -34.88 |
| Net Margin | -51.85 | -75 | -48.08 | -40 | -62.79 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company demonstrates mixed efficiency ratios. While it excels in receivables management, its fixed asset and capital turnover are low, and inventory management is average. High receivables turnover and quick collection periods indicate effective credit policies. However, inefficient use of fixed assets and capital, along with moderate inventory turnover, suggest operational inefficiencies. Improvement in asset utilization and inventory control could enhance overall efficiency and profitability.
| Efficiency Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 0.46 | 0.43 | 0.35 | 0.33 | 0.29 |
| Inventory Turnover Ratio | 4.58 | 4.74 | 4 | 6.07 | 8.21 |
| Receivables Turnover Ratio | 182.5 | 73 | 91.25 | 26.07 | |
| Days Sales in Inventory Ratio | 79.69 | 77 | 91.25 | 60.13 | 44.46 |
| Receivable Days | 2 | 5 | 4 | 14 | 0 |
| Capital Turnover Ratio | 1.8 | -0.83 | -0.93 | -0.77 | -0.37 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's coverage ratios are very low, indicating a weak ability to meet its interest and dividend obligations. Negative interest coverage ratio and lack of equity dividend coverage raise concerns about financial risk. Low coverage ratios could limit the company's ability to leverage debt and sustain dividend payments. Addressing this issue is vital for maintaining financial stability.
| Coverage Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | -3.67 | -8 | -7.33 | -3 | -3.5 |
| Equity Dividend Coverage Ratio |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company's solvency ratios present a mixed picture. While the Debt to Equity ratio is strong, The high debt ratio and very high debt to asset ratio suggest reliance on debt financing, while the negative equity ratio indicates financial distress. Overall, while there are some strengths, the company's solvency is concerning due to high debt levels and negative equity, which could pose risks to its long-term financial stability.
| Solvency Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Debt Ratio | 1.7 | 2.29 | 2.34 | 2.83 | 10.73 |
| Debt to Equity Ratio | -2.43 | -1.78 | -1.75 | -1.55 | -1.1 |
| Equity Ratio | -0.7 | -1.29 | -1.34 | -1.83 | -9.73 |
| Debt To Asset Ratio | 0.64 | 0.7 | 0.99 | 1.03 | 0.95 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position is weak, indicating potential difficulties in meeting short-term obligations. Low current, quick, and cash ratios suggest limited liquid assets to cover immediate liabilities. Negative operating cash flow ratios further exacerbate these concerns, reflecting poor cash generation from core operations. This situation could impact the company's ability to invest in growth opportunities or handle unexpected financial challenges. While the industry might face seasonal fluctuations, the consistently low ratios point to more structural issues that need attention.
| Liquidity Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Current Ratio | 0.29 | 0.33 | 0.24 | 0.23 | 0.13 |
| Quick Ratio | 0.12 | 0.13 | 0.12 | 0.14 | 0.09 |
| Cash Ratio | 0.01 | 0 | 0 | 0 | 0 |
| Operating Cash Flow Ratio | -0.15 | -0.13 | -0.25 | 0.02 | -0.05 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Par Drugs & Chemicals Ltd | 7.40 | 8.91 | Undervalued | 17.00 | 10.65 | 13.00 |
| 2 | Vaishali Pharma Ltd | 6.74 | 103.62 | Overvalued | 4.00 | 0.31 | 4.00 |
| 3 | Quest Laboratories Ltd | 5.27 | 11.21 | Neutral | 18.00 | 9.16 | 15.00 |
| 4 | Sotac Pharmaceuticals Ltd | 5.27 | 21.26 | Neutral | 18.00 | 4.45 | 6.00 |
| 5 | Zenith Drugs Ltd | 4.63 | 7.52 | Neutral | 17.00 | 2.30 | 10.00 |
| 6 | Krebs Biochemicals & Industries Ltd | 4.16 | -5.27 | Highly Undervalued | -4.00 | -12.49 | -4.00 |
The management effectiveness of Krebs Biochemicals & Industries Ltd appears weak. The company exhibits negative profit margins, inconsistent sales growth, and negative returns on capital employed. While promoter holding is high, the negative financial performance raises concerns about management's ability to steer the company towards profitability and sustainable growth. The company's reliance on debt financing, coupled with its inability to generate profits, further exacerbates the situation. Absence of dividend payouts reflects the poor financial health.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Promoter Holding | 72.74% | High promoter holding indicates alignment with shareholders. |
| CONS | Sales Growth (TTM) | -14% | Declining sales growth. |
| Operating Profit Margin (Mar 2025) | -88.69% | Poor operational efficiency. | |
| Return on Capital Employed (ROCE) | -30% | Inefficient use of capital. |
Financial Performance & Growth
Krebs Biochemicals showcases weak financial performance and inconsistent growth. Sales Growth % for the recent quarters shows volatility. The company has been consistently reporting negative Operating Profit Margin (OPM) %. The OPM % reached -88.69% in Mar 2025, indicating deteriorating operational efficiency. Further, net profit is negative, highlighting fundamental profitability issues.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Sales Growth (%) | 11.17% | 57.40% | 74.79% | -58.32% | -12.68% | -3.28% | -14.10% |
| OPM (%) | -51.04% | -58.93% | -9.07% | -32.78% | -40.31% | -26.07% | -88.69% |
Capital Efficiency & Returns
The capital efficiency and returns for Krebs Biochemicals are poor. The company's Return on Capital Employed (ROCE) is negative, indicating that capital is not being used productively. The ROCE % has been fluctuating in negative territory. The negative ROCE over the years indicates consistent underperformance in utilizing capital to generate returns.
| Metric | Mar 2016 | Mar 2019 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| ROCE (%) | -26% | -36% | -57% | -29% | -19% | -30% |
Financial Health & Prudence
The financial health of Krebs Biochemicals is weak due to increasing borrowings and negative net worth. Borrowings have generally increased over the years. This indicates increasing financial leverage. The company's negative book value further indicates financial distress.
| Metric | Mar 2016 | Mar 2019 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Borrowings | 31 | 53 | 143 | 183 | 194 | 212 |
| Book Value | -0 | -31 | -97 | -121 | -141 | -168 |
Shareholding & Ownership Structure
The shareholding pattern indicates a high promoter holding. Promoter holding is consistently high. FII holding is minimal.
| Metric | Mar 2017 | Mar 2019 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Promoter Holding | 59.77% | 64.66% | 72.74% | 72.74% | 72.74% | 72.74% |
| FII Holding | 0.01% | 0.01% | 0.01% | 0.50% | 0.50% | 0.50% |
Krebs Biochemicals & Industries Ltd exhibits high financial risk due to negative profit margins, inconsistent sales, and negative ROCE which highlight operational inefficiencies. Increasing borrowings and negative net worth raise concerns about long-term viability. These factors contribute to a high-risk profile.
Off-balance sheet exposure quantification
There is no specific data available on off-balance sheet exposure quantification.
Contingent liability evaluation
There is no specific data available on contingent liability evaluation.
Segment performance volatility
There is no specific data available on segment performance volatility.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1065.31Bullish
- SMA 2065.51Bullish
- SMA 5065.43Bullish
- EMA 1065.49Bullish
- EMA 2065.52Bullish
- EMA 5065.56Bullish
- DEMA 1065.50Bullish
- DEMA 2065.44Bullish
- DEMA 5065.73Bullish
- TEMA 1065.60Bullish
- TEMA 2065.42Bullish
- TEMA 5065.27Bullish
- MACD-0.06Bullish
- ADX14.37Weak Trend
- IndicatorValueSignal
- RSI52.39Neutral
- CCI10.61Neutral
- ROC 9-0.17Bearish
- ROC 141.38Bullish
- ROC 254.16Bullish
- Stoch K47.27Neutral
- Stoch D47.68Neutral
- IndicatorValueSignal
- BB Upper66.67Neutral
- BB Middle65.50Neutral
- BB Lower64.34Neutral
- ATR0.93Low Volatility
- IndicatorValueSignal
- MFI49.43Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1065.32Bullish
- SMA 2065.61Bullish
- SMA 5065.76Bullish
- EMA 1065.46Bullish
- EMA 2065.51Bullish
- EMA 5065.21Bullish
- DEMA 1065.42Bullish
- DEMA 2065.43Bullish
- DEMA 5066.29Bearish
- TEMA 1065.47Bullish
- TEMA 2065.31Bullish
- TEMA 5065.71Bullish
- MACD-0.06Bearish
- ADX26.49Strong Trend
- IndicatorValueSignal
- RSI51.82Neutral
- CCI-5.05Neutral
- ROC 91.37Bullish
- ROC 141.53Bullish
- ROC 255.92Bullish
- Stoch K44.70Neutral
- Stoch D44.25Neutral
- IndicatorValueSignal
- BB Upper67.22Neutral
- BB Middle65.61Neutral
- BB Lower64.00Neutral
- ATR1.58Low Volatility
- IndicatorValueSignal
- MFI66.19Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1065.55Bullish
- SMA 2065.83Bullish
- SMA 5063.32Bullish
- EMA 1065.53Bullish
- EMA 2065.39Bullish
- EMA 5063.77Bullish
- DEMA 1065.52Bullish
- DEMA 2066.01Bearish
- DEMA 5066.67Bearish
- TEMA 1065.46Bullish
- TEMA 2065.44Bullish
- TEMA 50N/AN/A
- MACD0.38Bearish
- ADX33.61Strong Trend
- IndicatorValueSignal
- RSI52.59Neutral
- CCI-28.97Neutral
- ROC 9-1.49Bearish
- ROC 140.05Bullish
- ROC 252.94Bullish
- Stoch K47.17Neutral
- Stoch D45.46Neutral
- IndicatorValueSignal
- BB Upper68.14Neutral
- BB Middle65.83Neutral
- BB Lower63.53Neutral
- ATR2.51Low Volatility
- IndicatorValueSignal
- MFI71.08Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1065.62Bearish
- SMA 2064.48Bearish
- SMA 5061.53Bullish
- SMA 10058.18Bullish
- SMA 20064.03Bullish
- EMA 1065.13Bearish
- EMA 2064.13Bullish
- EMA 5061.60Bullish
- EMA 10061.22Bullish
- EMA 20064.47Bearish
- DEMA 1065.71Bearish
- DEMA 2066.25Bearish
- DEMA 5063.98Bullish
- DEMA 10059.34Bullish
- DEMA 20057.41Bullish
- TEMA 1065.09Bearish
- TEMA 2066.29Bearish
- TEMA 5066.72Bearish
- TEMA 10062.49Bullish
- TEMA 20056.41Bullish
- MACD1.50Bearish
- ADX24.58Weak Trend
- IndicatorValueSignal
- RSI52.61Neutral
- CCI19.26Neutral
- ROC 14-1.30Bearish
- ROC 259.84Bullish
- Stoch K44.97Neutral
- Stoch D49.49Neutral
- IndicatorValueSignal
- BB Upper69.98Neutral
- BB Middle64.48Neutral
- BB Lower58.97Neutral
- ATR3.96Low Volatility
- IndicatorValueSignal
- MFI73.94Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 2057.50Bullish
- SMA 5066.37Bearish
- EMA 2060.67Bullish
- EMA 5065.52Bearish
- DEMA 2058.94Bullish
- DEMA 5057.73Bullish
- TEMA 2061.81Bullish
- TEMA 5055.56Bullish
- MACD-0.72Bullish
- ADX17.40Weak Trend
- IndicatorValueSignal
- RSI51.06Neutral
- CCI-3.67Neutral
- ROC 1420.77Bullish
- ROC 25-6.05Bearish
- Stoch K81.21Overbought
- Stoch D75.80Neutral
- IndicatorValueSignal
- BB Upper68.85Neutral
- BB Middle57.50Neutral
- BB Lower46.14Neutral
- ATR7.46High Volatility
- IndicatorValueSignal
- MFI84.77Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 658.25Bullish
- SMA 1266.17Bearish
- SMA 2474.83Bearish
- EMA 660.13Bullish
- EMA 1264.34Bullish
- EMA 2470.84Bearish
- DEMA 657.22Bullish
- DEMA 1257.05Bullish
- DEMA 2459.96Bullish
- TEMA 659.23Bullish
- TEMA 1255.20Bullish
- TEMA 2458.11Bullish
- MACD-11.81Bearish
- ADX26.54Strong Trend
- IndicatorValueSignal
- RSI46.88Neutral
- CCI-76.32Neutral
- ROC 25-8.68Bearish
- ROC 50-54.45Bearish
- Stoch K17.22Oversold
- Stoch D28.74Neutral
- IndicatorValueSignal
- BB Upper102.84Neutral
- BB Middle73.36Neutral
- BB Lower43.87Neutral
- ATR19.08Low Volatility
- IndicatorValueSignal
- MFI74.52Neutral